Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial

Blood (2019) 134 (Supplement_1): 373.

https://doi.org/10.1182/blood-2019-131925

Published: 2019

Journal Articles

Clinical Utility of a Multi-Gene Next-Generation Sequencing Myeloid Panel in an Academic Hematology Practice

Pedro G Vianna, BSc,MD, Richard D. Press, MD PhD, Henning Stehr, PhD, Fei Yang, MD, Linda Gojenola, James L Zehnder, Jason Gotlib, MD MS

Blood (2019) 134 (Supplement_1): 1408.

https://doi.org/10.1182/blood-2019-124445

Published: 2019

Journal Articles

Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort

Daniel Bottomly, Nicola Long, Fei Yang, MD, Tiffany Lee, MD, Uma Borate, MD, Beth Wilmot, PhD, Adam S DuVall, MD, Andrea Monteblanco, BS, Karina Thiel-Klare, Gabby Dewson, BA, Richard D. Press, MD PhD, Cristina E. Tognon, Brian J. Druker, Jeffrey W. Tyner, Shannon K. McWeeney, PhD, Anupriya Agarwal, PhD

Blood (2019) 134 (Supplement_1): 1407.

https://doi.org/10.1182/blood-2019-132224

Published: 2019

Journal Articles

Mutations Modifying Risk in NPM1+ AML

Jessica Leonard, MD, Jennifer Dunlap, MD, Tanaya L Neff, Andrea Warrick, Fei Yang, Richard D. Press, MD PhD, Brian J. Druker, MD, Elie Traer, MD, PhD

Blood (2015) 126 (23): 2592.

https://doi.org/10.1182/blood.V126.23.2592.2592

Published: 2015

Journal Articles

Clinical Evaluation of Xpert® BCR-ABL Ultra, an Automated and Standardized Cartridge-Based Assay for the Quantification of BCR-ABL1

Michael J. Mauro, MD, Richard D. Press, MD PhD, David S. Snyder, MD, Qin Huang, MD PhD, Javier Pinilla-Ibarz, Dahui Qin, MD PhD, Christina Lockwood, PhD, Jacqueline E. Payton, MD PhD, Geoffrey L. Uy, MD, Matt E. Kalaycio, MD, Ramon V. Tiu, MD BS, Vivian Oehler, MD, Gwo-Jen Day, PhD, Wendy Wong, Michael P. Bates, MD, Jerald P. Radich

Blood (2015) 126 (23): 5170.

https://doi.org/10.1182/blood.V126.23.5170.5170

Published: 2015

Journal Articles

ERG, BAALC, and MN1 RNA Levels Are Correlatively Over-Expressed, and Relate to Risk-Defining Prognostic Mutations in Intermediate-Risk Acute Myeloid Leukemia

Fei Yang, Franklin Moore, M.D., Ph.D., Dean Westberry, Miriam Hough, Julie Partain, William H Fleming, MD, PhD, Tibor Kovacsovics, MD, Richard D. Press, MD, PhD

Blood (2011) 118 (21): 1471.

https://doi.org/10.1182/blood.V118.21.1471.1471

Published: 2011

Journal Articles

Clinical Outcomes In Patients with Chronic Myelogenous Leukemia (CML) and the BCR-ABL 35 Base Pair (bp) Intron 8 Insertion Mutation.

Ellin Berman, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Thomas O'Hare, PhD, Christopher Eide, BS, Richard D. Press, MD, PhD, Brian J Druker, MD, Cyrus V. Hedvat, MD, PhD

Blood (2010) 116 (21): 3408.

https://doi.org/10.1182/blood.V116.21.3408.3408

Published: 2010

Journal Articles

Comparison of Different Laboratory Methods for Quantification of BCR-ABL Kinase Domain Mutations In CML Patients Undergoing Tyrosine Kinase Inhibitor Therapy

Richard D. Press, MD, PhD, Fei Yang

Blood (2010) 116 (21): 2760.

https://doi.org/10.1182/blood.V116.21.2760.2760

Published: 2010

Journal Articles

Determining the Rise in BCR-ABL RNA That Optimally Predicts a Kinase Domain Mutation in Patients with CML on Imatinib.

Richard D. Press, MD, PhD, Stephanie G Willis, Jennifer Laudadio, Michael J. Mauro, MD, Michael W.N. Deininger, MD

Blood (2008) 112 (11): 1108.

https://doi.org/10.1182/blood.V112.11.1108.1108

Published: 2008

Journal Articles

BCR-ABL Transcript Levels at Time of Complete Cytogenetic Remission Achieved after Salvage with Dasatinib or Nilotinib.

Michael J. Mauro, MD, Richard D. Press, MD, PhD, Michael W. Deininger, MD, PhD, Brian J. Druker, MD

Blood (2007) 110 (11): 1945.

https://doi.org/10.1182/blood.V110.11.1945.1945

Published: 2007

Journal Articles

An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Three CML Patients Undergoing Kinase Inhibitor Therapy.

Jennifer Laudadio, MD, Michael W.N. Deininger, MD, Michael J. Mauro, MD, Brian J. Druker, MD, Richard D. Press, MD, PhD

Blood (2007) 110 (11): 1953.

https://doi.org/10.1182/blood.V110.11.1953.1953

Published: 2007

Journal Articles

Characterization of BCR-ABL Deletion Mutants from Patients with Chronic Myeloid Leukemia.

Daniel W. Sherbenou, BA, Oliver J. Hantschel, PhD, Lalita Turaga, BS, Ines Kaupe Mag, Stephanie Willis, BS, Thomas Bumm, MD, Richard D. Press, MD, PhD, Giulio Superti-Furga, PhD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2007) 110 (11): 2936.

https://doi.org/10.1182/blood.V110.11.2936.2936

Published: 2007

Journal Articles

A Half-Log Increase in Quantitative RT-PCR for BCR-ABL (RQ-PCR) as a Trigger for Kinase Domain Mutation Analysis.

Richard D. Press, MD, PhD, Stephanie Willis, Carole Rempfer, Michael J. Mauro, MD, Brian J. Druker, MD, Michael W.N. Deininger, MD

Blood (2006) 108 (11): 2152.

https://doi.org/10.1182/blood.V108.11.2152.2152

Published: 2006

Journal Articles

In Chronic Myeloid Leukemia (CML) Patients with Complete Cytogenetic Response to Imatinib, BCR-ABL Kinase Domain Mutations Are Relatively Rare and Not Consistently Associated with Subsequent Relapse.

Daniel W. Sherbenou, Matthew J. Wong, Adil Humayun, Laura S. McGreevey, Rui Yang, MD, Michael C. Heinrich, MD, Richard D. Press, MD, PhD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2005) 106 (11): 434.

https://doi.org/10.1182/blood.V106.11.434.434

Published: 2005

Journal Articles

BCR-ABL RNA Levels at the Time of a Complete Cytogenetic Response (CCR) Predict the Duration of CCR in Imatinib-Treated Chronic Myeloid Leukemia Patients.

Richard D. Press, MD, PhD, Zac Love, Ashlie A. Tronnes, Gwen Kurilik, Michael J. Mauro, MD, Michael W. Deininger, MD, PhD, Brian J. Druker, MD

Blood (2004) 104 (11): 1098.

https://doi.org/10.1182/blood.V104.11.1098.1098

Published: 2004

NARROW

Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial

Clinical Utility of a Multi-Gene Next-Generation Sequencing Myeloid Panel in an Academic Hematology Practice

Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort

Mutations Modifying Risk in NPM1+ AML

Clinical Evaluation of Xpert® BCR-ABL Ultra, an Automated and Standardized Cartridge-Based Assay for the Quantification of BCR-ABL1

ERG, BAALC, and MN1 RNA Levels Are Correlatively Over-Expressed, and Relate to Risk-Defining Prognostic Mutations in Intermediate-Risk Acute Myeloid Leukemia

Clinical Outcomes In Patients with Chronic Myelogenous Leukemia (CML) and the BCR-ABL 35 Base Pair (bp) Intron 8 Insertion Mutation.

Comparison of Different Laboratory Methods for Quantification of BCR-ABL Kinase Domain Mutations In CML Patients Undergoing Tyrosine Kinase Inhibitor Therapy

Determining the Rise in BCR-ABL RNA That Optimally Predicts a Kinase Domain Mutation in Patients with CML on Imatinib.

BCR-ABL Transcript Levels at Time of Complete Cytogenetic Remission Achieved after Salvage with Dasatinib or Nilotinib.

An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Three CML Patients Undergoing Kinase Inhibitor Therapy.

Characterization of BCR-ABL Deletion Mutants from Patients with Chronic Myeloid Leukemia.

A Half-Log Increase in Quantitative RT-PCR for BCR-ABL (RQ-PCR) as a Trigger for Kinase Domain Mutation Analysis.

In Chronic Myeloid Leukemia (CML) Patients with Complete Cytogenetic Response to Imatinib, BCR-ABL Kinase Domain Mutations Are Relatively Rare and Not Consistently Associated with Subsequent Relapse.

BCR-ABL RNA Levels at the Time of a Complete Cytogenetic Response (CCR) Predict the Duration of CCR in Imatinib-Treated Chronic Myeloid Leukemia Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only